Search results
Results from the WOW.Com Content Network
The ongoing outbreak in Japan has already surpassed last year’s previous record of 941 preliminary infections – the highest since statistics began in 1999. Japan’s National Institute of ...
Japan is experiencing a record-setting number of streptococcal toxic shock syndrome (STSS) cases. STSS is a rare but severe complication of Group A Streptococcus infection, the same bacteria ...
Uromune, also known by its developmental code name MV-140, is a polyvalent bacterial vaccine which is used and is being developed for prevention of recurrent urinary tract infections (UTIs). [ 1 ] [ 2 ] [ 3 ] In clinical studies , it has been found to reduce total number of UTIs by about 70%, to increase UTI-free rates from around 25% to 57% ...
In April 2021, prime minister Suga Yoshihide announced that Japan will receive 50 million doses of the Pfizer vaccine after a meeting with the company's CEO. [ 4 ] [ 33 ] The roll out of the vaccines in Japan, with 4 percent of the population inoculated as of May 21, 2021, has led to criticisms of slow approval, disruptions on import, and the ...
Bacillus cereus infection Culture Vancomycin: No multiple bacteria Bacterial meningitis: Lumbar puncture (contraindicated if there is a mass in the brain or the intracranial pressure is elevated), CT or MRI Antibiotics No multiple bacteria Bacterial pneumonia: Sputum Gram stain and culture, Chest radiography Antibiotics No
Sanofi-Aventis's ActHIB vaccine protects against haemophilus influenzae type b (Hib), one of the most common causes of bacterial meningitis (an infection of the covering of the brain and spinal cord).
With the conjugate vaccine about 10% of babies develop redness at the site of injection, fever, or change in sleep. [1] Severe allergies are very rare. [1] Whole-cell vaccinations were developed alongside characterisation of the subtypes of pneumococcus from the early 1900s. [5] The first pneumococcal vaccine was developed in the 1980s. [1]
On August 7, 2015, it was designated as the first BSL-4 facility in Japan for detailed examination and development of therapeutic agents for patients suspected of being infected with Ebola due to the 2014 West African Ebola epidemic. [2] [3]